Latest News
Web Date: May 19, 2014

AstraZeneca Rejects ‘Final’ Pfizer Offer

Acquisitions: Deal not sweet enough to make British firm bend to merger pressure
Department: Business
Keywords: pharmaceuticals, acquisitions, taxation, R&D, employment

AstraZeneca’s management has rejected Pfizer’s fourth and presumably final takeover offer, this one valued at $119 billion.

“We have rejected Pfizer’s final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the company, our employees, and the life-sciences sector in the U.K., Sweden, and the U.S.,” AstraZeneca Chairman Leif Johansson said. Even if key concerns around a merger had been satisfactorily addressed, . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society